Trial Profile
The Efficacy of Denosumab to Prevent Bone Loss in Ambulatory and Non-ambulatory Motor-Incomplete Patients With Subacute Spinal Cord Injury
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 13 Mar 2024 Status changed from recruiting to discontinued.
- 27 Feb 2018 Status changed from not yet recruiting to recruiting.
- 02 Feb 2017 New trial record